cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Immunovant Inc
21 own
8 watching
Current Price
$29.6
$0.2
(0.66%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
4,465.67M
52-Week High
52-Week High
45.58000
52-Week Low
52-Week Low
24.67000
Average Volume
Average Volume
0.34M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization4,465.67M
icon52-Week High45.58000
icon52-Week Low24.67000
iconAverage Volume0.34M
iconDividend Yield--
iconP/E Ratio--
What does the Immunovant Inc do?
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Read More
How much money does Immunovant Inc make?
News & Events about Immunovant Inc.
Zolmax
1 year ago
Shares of Immunovant, Inc. (NASDAQ:IMVT Get Rating) have been assigned an average rating of Moderate Buy from the eleven brokerages that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the ...
Zolmax
1 year ago
Immunovant, Inc. (NASDAQ:IMVT Get Rating) CEO Peter Salzmann sold 3,395 shares of the companys stock in a transaction on Tuesday, April 18th. The shares were sold at an average price of $15.27, for a total value of $51,841.65. Following the transaction, the chief executive officer now directly owns ...
Ticker Report
1 year ago
Immunovant, Inc. (NASDAQ:IMVT Get Rating) CFO Eva Renee Barnett sold 3,423 shares of the firms stock in a transaction on Tuesday, April 18th. The shares were sold at an average price of $15.27, for a total value of $52,269.21. Following the sale, the chief financial officer now ...
Zolmax
1 year ago
Immunovant, Inc. (NASDAQ:IMVT Get Rating) Research analysts at HC Wainwright lifted their FY2026 earnings per share estimates for Immunovant in a research note issued on Monday, March 20th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings per share of ($1.19) for the...
Benzinga
1 year ago
Latest Ratings for IMVT DateFirmActionFromTo Dec 2021Wells FargoInitiates Coverage OnEqual-Weight Nov 2021HC Wainwright & Co.MaintainsBuy Aug 2021BairdDowngradesOutperformNeutral View More Analyst Ratings for IMVT View the Latest Analyst Ratings read more...
Frequently Asked Questions
Frequently Asked Questions
What is Immunovant Inc share price today?
plus_minus_icon
Can Indians buy Immunovant Inc shares?
plus_minus_icon
How can I buy Immunovant Inc shares from India?
plus_minus_icon
Can Fractional shares of Immunovant Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Immunovant Inc stocks?
plus_minus_icon
What is today’s traded volume of Immunovant Inc?
plus_minus_icon
What is today’s market capitalisation of Immunovant Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Immunovant Inc?
plus_minus_icon
What percentage is Immunovant Inc down from its 52-Week High?
plus_minus_icon
What percentage is Immunovant Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$29.6
$0.2
(0.66%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals Inc
$27.38
$-0.07 (-0.26 %)
Vaxcyte Inc
Vaxcyte Inc
$111.74
$3.28 (3.02 %)
Bridgebio Pharma Inc
Bridgebio Pharma Inc
$24.76
$-0.08 (-0.32 %)
Rocket Pharmaceuticals Inc
Rocket Pharmaceuticals Inc
$17.25
$0.48 (2.89 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals Inc
$27.38
$-0.07 (-0.26 %)
Vaxcyte Inc
Vaxcyte Inc
$111.74
$3.28 (3.02 %)
Bridgebio Pharma Inc
Bridgebio Pharma Inc
$24.76
$-0.08 (-0.32 %)
Rocket Pharmaceuticals Inc
Rocket Pharmaceuticals Inc
$17.25
$0.48 (2.89 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.

              Borderless Softtech Pvt Ltd ("BSPL") licenses and offers the Stockal Platform to subscribers and users who are based in India and wish to make global transactions. Such subscribers and users may be offered annual or monthly subscription plans by BSPL and in such cases, BSPL acts as their service provider.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00